SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

CAMP4 Gets EU CTA Approval for Phase 1/2 CMP-002 Trial

CAMP4 received Clinical Trial Application approval for its Phase 1/2 ASCEND trial of CMP-002 in SYNGAP1-related disorder.

CAMP

Related stories